Hundreds of cystic fibrosis patients become eligible for ‘life-changing' therapy
CF is caused by a faulty gene that affects the production of a protein called CFTR.
Modulator drugs work by helping to make the CFTR protein work effectively.
NHS officials said the treatments can 'transform' life expectancy and quality of life for patients.
There are a number of modulator therapies available but some patients with the rarest forms of the disease have been unable to access them until now.
Nice approved Alyftrek, which is known as a triple therapy, for patients aged six and over for the most common form of CF as an alternative to another treatment called Kaftrio.
And NHS England announced that the treatment would also be made available for children and adults with rare forms of cystic fibrosis, who have not previously been eligible for modulator therapy.
NHS England said the move allows patients with the rarest form of the disease to access the latest treatments, including Alyftrek and Kaftrio, for the first time.
It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy.
The new drug, also known as vanza triple, has been found to be as effective as current drug Kaftrio in clinical trials in improving and maintaining lung function in people with CF.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved the triple combination medicine – which is also known as deutivacaftor/tezacaftor/vanzacaftor – for use in the UK, for certain patients with CF over the age of six, in March.
Cystic fibrosis is a genetic condition that causes thick mucus to build up in the lungs and digestive system which leads to breathing difficulties and serious infections.
John Stewart, NHS England's director for specialised commissioning, said: 'This is a major leap forward for hundreds of patients living with the rarest forms of cystic fibrosis, offering fresh hope of a better quality of life.
'Access to a once-daily treatment at home can make an enormous difference to patients and their families – reducing the burden of hospital appointments and allowing children and young people to live more freely and independently.
'For those living with the rarest forms of the condition, this represents the very first time they will be able to access this new standard of care that has been so transformative for many since 2019.
'The rollout of this life-changing therapy demonstrates how the NHS continues to embrace innovation to deliver significant improvements in care for patients across the country at a fair price for the taxpayer.'
Helen Knight, director of medicines evaluation at Nice, said: 'CFTR modulators are already revolutionising the way cystic fibrosis is treated so we're pleased to be able to recommend Alyftrek, the latest of this type of treatment that has been shown to be effective, with significant benefits for people with the condition.'
David Ramsden, chief executive of the Cystic Fibrosis Trust, said: 'Today's announcements are another positive step in the journey to better treatments for everyone with cystic fibrosis – a lifelong, life-limiting condition without a cure.
'It's thanks to the incredible support and many years of campaigning of the CF community, and the work of all our partners, that modulator drugs are now a treatment option for thousands of people.'
Ludovic Fenaux, senior vice president at Vertex International, said the move 'represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
26 minutes ago
- Telegraph
‘Cosmetic cowboys' to be banned from carrying out Brazilian butt lifts
'Cosmetic cowboys' will be banned from performing high-risk procedures under new Government plans. The crackdown follows incidents in which patients have been maimed, and deaths linked to poor care and rogue operators. Under the measures, only qualified healthcare professionals such as doctors and nurses will be able to deliver procedures such as Brazilian butt lifts. These will only be able to be carried out by providers regulated by the health regulator, the Care Quality Commission. Clinics administering Botox and fillers will have to meet new standards and be licenced by councils. Under-18s will be banned from high risk procedures, such as injectables, amid concerns that children needed to be protected from 'dangerous beauty trends on social media'. Health officials said the steps aimed to protect the public from 'rogue operators' with no medical training, who often provided 'invasive' procedures in homes, hotels and pop-up clinics. The move would also reduce the cost imposed upon the NHS to fix botched procedures, the Department of Health and Social Care said. Karin Smyth, the health minister, said: 'The cosmetics industry has been plagued by a wild west of dodgy practitioners and procedures. There are countless horror stories of 'cosmetic cowboys' causing serious, catastrophic damage. 'This Government is taking action to protect those seeking treatments, support honest and competent practitioners, and root out the cowboys as part of our Plan for Change. 'This isn't about stopping anyone from getting treatments – it's about preventing rogue operators from exploiting people at the expense of their safety and keeping people safe. We're giving them peace of mind and reducing the cost to the NHS of fixing botched procedures.' Those who break the rules on high-risk procedures could face sanctions from the watchdog and financial penalties. The department said it would launch a consultation next year, seeking views on the range of procedures that should be covered by the new restrictions. Last month, the Chartered Trading Standards Institute warned that fat injections, Brazilian butt lifts, Botox and fillers are being offered by untrained people in places such as public toilets. There have also been concerns about rising numbers of people poisoned by fake Botox, leaving consumers struggling with breathing and swallowing problems, and slurred speech, after suffering from botulism. Millie Kendall, the chief executive of the British Beauty Council, said: 'Any measures that increase protection for the general public and professionalise the industry will help instil confidence, as well as helping to prevent the normalisation of horror stories that have become synonymous with our sector.' Ashton Collins, the director of Save Face, a register of accredited practitioners, said: 'I am delighted that the Government has recognised the significant and potentially fatal risks posed by highly dangerous procedures like liquid Brazilian butt lifts and has made it a priority to implement restrictions to protect public safety. 'I have seen first-hand the devastating impact these procedures can have on the lives of victims and their families, none more so than the family of Alice Webb.' Webb died last year, aged 33, after suffering complications from having a non-surgical Brazilian butt lift, which involved cosmetic fluid being injected into her buttocks. The mother-of-five worked in the beauty industry and lived in Gloucestershire.
The Independent
an hour ago
- The Independent
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.
Daily Mirror
2 hours ago
- Daily Mirror
'My son hasn't had a glass of water since he was four - and I understand why'
A new survey has revealed four in ten Brits rely on cups of tea to stay hydrated - and one mum has said her son hasn't drunk a glass of water in five years because it's "boring" More than two and a half million Brits struggle to recall the last time they had a plain glass of water. Research has discovered almost half rely primarily on cups of tea to stay hydrated, with a third opting for coffee or fizzy drinks. Boomers are twice as likely as Gen Z to rely on tea for their fluid intake. Meanwhile, women are more likely than men to fail to drink enough water. The survey based on 2,000 adults found only 17 per cent are consuming enough water, based on NHS guidance which suggests up to eight glasses a day. What's more, one in ten parents polled don't think their children drink enough each day. The study, which also surveyed 837 teenagers, discovered 15 per cent of them consume plain water only a few times a week at most, leaving many parents worried about their intake and three quarters having to 'force' their children to stay hydrated. It comes after a doctor's warning to people who drink even a 'single cup of tea'. Man called 999 for 'his own protection' - then ended up jailed himself One mum, Kelly Mulligan, 53, says her son, Max who is nine, hasn't had a glass of plain water since he was four years old. The youngster would rather drink apple juice, which Kelly dilutes with water to keep his sugar content down. "Max has never liked plain water he says there's no flavour," she said. "I don't drink plain water either. I can only drink carbonated water or tea." Kelly, from Brighton, who runs her own cleaning business, explained: "Max will take little sips of water if he needs to, but he's always thirsty and says plain water doesn't quench his thirst." Max has to take a bottle of water to school as they are not allowed anything else, but Kelly isn't sure how much of it he actually drinks. "He's healthy and happy, so I have no concerns. He has a varied diet and keeps active. It isn't like he's drinking no liquids at all. The diluted apple juice is a middle ground which helps keep my concerns for his teeth a bay," she said. According to the research commissioned by hydration drink Más+ by Messi, which is promoting positive hydration to keep Brits on top of their game, 34 per cent of 13–17 year olds prefer other beverages to water, while 26 per cent 'forget' to consume it. Meanwhile, 29 per cent of grown-ups reckoned tea, coffee and fizzy drinks are just as good as water for staying hydrated. However, 17 per cent regularly suffer symptoms they reckon are caused by dehydration, including headaches or tiredness. Only 12 per cent actively track their water consumption, with 60 per cent not bothering whatsoever – and the rest attempting to keep mental notes on their intake. Sophie Van Ettinger, global VP Más+ by Messi, said: "It's alarming the number of people who are not aware they are dehydrated daily and will often go through days experiencing a lack of energy or headaches, not realising a simple glass of water or even a hydration drink is the solution." Leo Messi, co-founder for the drink, added: "As an athlete, I know the importance of hydration for peak performance."
